Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Teacher Retirement System of Texas raised its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 18.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,144 shares of the biopharmaceutical company’s stock after purchasing an additional 6,644 shares during the quarter. Teacher Retirement System of Texas’ holdings in Arbutus Biopharma were worth $138,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Arbutus Biopharma by 50.2% during the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock valued at $16,967,000 after buying an additional 1,472,652 shares during the last quarter. Geode Capital Management LLC boosted its stake in Arbutus Biopharma by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,448,600 shares of the biopharmaceutical company’s stock valued at $13,280,000 after acquiring an additional 135,442 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Arbutus Biopharma by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,222,201 shares of the biopharmaceutical company’s stock worth $3,997,000 after acquiring an additional 9,955 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Arbutus Biopharma by 4.6% in the 3rd quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company’s stock worth $1,913,000 after purchasing an additional 21,807 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Arbutus Biopharma by 466.3% in the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company’s stock valued at $1,047,000 after purchasing an additional 223,995 shares in the last quarter. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Stock Up 0.9 %

Shares of NASDAQ:ABUS opened at $3.51 on Thursday. The company has a market cap of $665.12 million, a PE ratio of -8.16 and a beta of 1.93. Arbutus Biopharma Co. has a fifty-two week low of $2.30 and a fifty-two week high of $4.73. The firm has a 50-day simple moving average of $3.35 and a 200 day simple moving average of $3.54.

Arbutus Biopharma (NASDAQ:ABUS) last posted its earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. As a group, research analysts forecast that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ABUS shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Friday, March 28th. Finally, StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 29th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.